248 related articles for article (PubMed ID: 24215158)
1. Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?
Bedke J; Stenzl A
Expert Rev Anticancer Ther; 2013 Dec; 13(12):1399-408. PubMed ID: 24215158
[TBL] [Abstract][Full Text] [Related]
2. IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy.
Rausch S; Kruck S; Stenzl A; Bedke J
Future Oncol; 2014 May; 10(6):937-48. PubMed ID: 24941980
[TBL] [Abstract][Full Text] [Related]
3. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Kirner A; Mayer-Mokler A; Reinhardt C
Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
[TBL] [Abstract][Full Text] [Related]
4. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.
Soleimani A; Berntsen A; Svane IM; Pedersen AE
Scand J Immunol; 2009 Nov; 70(5):481-9. PubMed ID: 19874553
[TBL] [Abstract][Full Text] [Related]
5. Current immunotherapeutic strategies in renal cell carcinoma.
Amato RJ
Surg Oncol Clin N Am; 2007 Oct; 16(4):975-86, xi-xii. PubMed ID: 18022554
[TBL] [Abstract][Full Text] [Related]
6. T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective.
Shablak A; Hawkins RE; Rothwell DG; Elkord E
Clin Cancer Res; 2009 Nov; 15(21):6503-10. PubMed ID: 19843660
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for renal cell cancer.
Yang JC; Childs R
J Clin Oncol; 2006 Dec; 24(35):5576-83. PubMed ID: 17158543
[TBL] [Abstract][Full Text] [Related]
8. Antigenic targets for renal cell carcinoma immunotherapy.
Vieweg J; Jackson A
Expert Opin Biol Ther; 2004 Nov; 4(11):1791-801. PubMed ID: 15500407
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma.
Märten A; Renoth S; Heinicke T; Albers P; Pauli A; Mey U; Caspari R; Flieger D; Hanfland P; Von Ruecker A; Eis-Hübinger AM; Müller S; Schwaner I; Lohmann U; Heylmann G; Sauerbruch T; Schmidt-Wolf IG
Hum Gene Ther; 2003 Mar; 14(5):483-94. PubMed ID: 12691613
[TBL] [Abstract][Full Text] [Related]
10. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
12. IMA901: a peptide vaccine in renal cell carcinoma.
Bedke J; Stenzl A
Expert Opin Investig Drugs; 2013 Oct; 22(10):1329-36. PubMed ID: 23899354
[TBL] [Abstract][Full Text] [Related]
13. Lymphocyte therapy of renal cell carcinoma.
Dillman RO
Expert Rev Anticancer Ther; 2005 Dec; 5(6):1041-51. PubMed ID: 16336095
[TBL] [Abstract][Full Text] [Related]
14. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
15. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.
Mulders P; Tso CL; Gitlitz B; Kaboo R; Hinkel A; Frand S; Kiertscher S; Roth MD; deKernion J; Figlin R; Belldegrun A
Clin Cancer Res; 1999 Feb; 5(2):445-54. PubMed ID: 10037196
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.
Pandha HS; John RJ; Hutchinson J; James N; Whelan M; Corbishley C; Dalgleish AG
BJU Int; 2004 Aug; 94(3):412-8. PubMed ID: 15291878
[TBL] [Abstract][Full Text] [Related]
17. [Specific cellular immunotherapy of renal cell carcinoma. Current status and prospects].
Ringhoffer M; Gschwend JE
Urologe A; 2002 May; 41(3):249-57. PubMed ID: 12132274
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell-based vaccination for renal cell carcinoma: challenges in clinical trials.
Wang J; Liao L; Tan J
Immunotherapy; 2012 Oct; 4(10):1031-42. PubMed ID: 23148755
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapeutic approaches for renal cancer.
Pizza G; de Vinci C; Viza D
Folia Biol (Praha); 2002; 48(5):167-81. PubMed ID: 12448765
[No Abstract] [Full Text] [Related]
[Next] [New Search]